文献速递产科母胎医学

熊去氧胆酸对妊娠期糖尿病血糖影响的随机对照试验:GUARDS试验

Randomized controlled trial of the impact of ursodeoxycholic acid on glycemia in gestational diabetes mellitus: the GUARDS trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2025-07-09

这项单中心、随机、双盲、安慰剂对照试验纳入113名24至28周妊娠的妊娠期糖尿病患者,比较熊去氧胆酸与安慰剂对母体血糖的影响。主要结局(35+0至37+6周空腹血糖)在意向性分析中无显著差异(治疗效应0.98,95%CI 0.92-1.05,P=.61)。预设二次分析显示服药片数较多者血清熊去氧胆酸浓度较高;事后分析中,血清熊去氧胆酸≥0.5 µmol/L者空腹血糖超目标比例较低(2/42 [4.8%] vs 11/57 [19.3%];RR 0.25,95%CI 0.06-1.06,P=.039),作者提示值得进一步研究。

要点

  • 熊去氧胆酸组与安慰剂组主要结局空腹血糖无显著差异(治疗效应0.98,95%CI 0.92-1.05,P=.61)。
  • 母胎次要结局包括体重变化、胰岛素需求、出生体重百分位、大于/小于胎龄儿比例、新生儿低血糖及新生儿病房入住均无差异。
  • 事后分析中血清熊去氧胆酸≥0.5 µmol/L者空腹血糖超90 mg/dL比例较低(2/42 [4.8%] vs 11/57 [19.3%];RR 0.25,95%CI 0.06-1.06,P=.039)。

核心结论

  • 熊去氧胆酸组与安慰剂组妊娠期糖尿病孕妇的空腹血糖无差异。
  • 血清熊去氧胆酸浓度升高者空腹血糖低于推荐阈值的可能性更大,提示值得进一步研究。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照试验,纳入113名24至28周妊娠的妊娠期糖尿病患者。
  • 主要结局为35+0至37+6周妊娠时母体空腹血糖浓度。

主要发现

  • 主要结局在意向性分析中组间无显著差异(治疗效应0.98,95%CI 0.92-1.05,P=.61)。
  • 母体及胎儿次要结局包括母体体重变化、胰岛素治疗需求、出生体重百分位、大于或小于胎龄儿比例、新生儿低血糖或新生儿病房入住均无差异。
  • 预设二次分析采用超高效液相色谱-串联质谱法测定血清熊去氧胆酸浓度,显示服药片数较多者血清熊去氧胆酸浓度较高。
  • 事后分析显示意向性分析中空腹血糖≥推荐目标90 mg/dL的比例无差异(5/50 [10.0%] vs 8/53 [15.1%];RR 0.66,95%CI 0.23-1.89,P=.557)。
  • 血清熊去氧胆酸≥0.5 µmol/L(提示依从)者中,空腹血糖超目标比例较低(2/42 [4.8%] vs 11/57 [19.3%];RR 0.25,95%CI 0.06-1.06,P=.039)。

关键数值与推荐

  • 主要结局治疗效应0.98(95%CI 0.92-1.05,P=.61)。
  • 空腹血糖≥90 mg/dL的事后分析:5/50(10.0%)vs 8/53(15.1%);RR 0.66(95%CI 0.23-1.89,P=.557)。
  • 血清熊去氧胆酸≥0.5 µmol/L者空腹血糖超目标:2/42(4.8%)vs 11/57(19.3%);RR 0.25(95%CI 0.06-1.06,P=.039)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gestational diabetes mellitus is a pregnancy complication that can be associated with increased risks of adverse maternal and neonatal outcomes. Optimal glycemic control remains challenging for many patients despite the existing management strategies. Ursodeoxycholic acid is commonly used for cholestasis of pregnancy and has shown potential metabolic benefits, including improved insulin sensitivity and reduced inflammation. We hypothesize that ursodeoxycholic acid may improve glycemic control in gestational diabetes mellitus. OBJECTIVE: This study aimed to compare treatment with ursodeoxycholic acid vs placebo for improving maternal glycemia in gestational diabetes mellitus. STUDY DESIGN: This was a single-site, randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in 113 women with gestational diabetes mellitus at 24 to 28 weeks' gestation. The primary outcome was maternal fasting blood glucose concentration at 35+0 to 37+6 weeks' gestation. RESULTS: The primary outcome did not differ significantly between groups when evaluated by intention to treat analysis (treatment effect, 0.98; 95% confidence interval, 0.92-1.05; P=.61). There were no differences in maternal or fetal secondary outcomes, including maternal weight change, need for insulin treatment, birthweight centile, proportion of large or small for gestational age infants, neonatal hypoglycemia, or admission to the neonatal unit. A prespecified secondary analysis measured serum concentrations of ursodeoxycholic acid using ultra-performance liquid chromatography-tandem mass spectrometry and showed that participants taking larger numbers of tablets had higher serum concentrations of ursodeoxycholic acid. Post hoc analysis revealed no difference in the rate of fasting blood glucose concentrations at or above the recommended target of 90 mg/dL according to intention to treat analysis (5/50 [10.0%] vs 8/53 [15.1%]; risk ratio, 0.66; 95% confidence interval, 0.23-1.89; P=.557). However, among patients with serum ursodeoxycholic acid ≥0.5 µmol/L (indicating adherence), fewer patients had fasting glucose levels above the target (2/42 [4.8%] vs 11/57 [19.3%]; risk ratio, 0.25; 95% confidence interval, 0.06-1.06; P=.039). CONCLUSION: This trial demonstrated no difference in fasting glycemia between women with gestational diabetes mellitus treated with ursodeoxycholic acid and those treated with placebo. However, those with elevated serum ursodeoxycholic acid concentrations were more likely to have fasting blood glucose concentrations below the recommended thresholds, suggesting potential benefit of further investigation.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Matallana CP, Blanco-Carnero JE, Calabuig AC, et al. Randomized controlled trial of the impact of ursodeoxycholic acid on glycemia in gestational diabetes mellitus: the GUARDS trial. Am J Obstet Gynecol MFM. 2025. PMID: 40645453. doi:10.1016/j.ajogmf.2025.101732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。